Email This Release
Phase III Study (SATURN) Showed Tarceva Improved Progression-Free Survival as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer
*
marks required fields
Recipient Name:
*
Recipient Email:
Message:
